Literature DB >> 15939870

A general method for greatly improving the affinity of antibodies by using combinatorial libraries.

Arvind Rajpal1, Nurten Beyaz, Lauric Haber, Guido Cappuccilli, Helena Yee, Ramesh R Bhatt, Toshihiko Takeuchi, Richard A Lerner, Roberto Crea.   

Abstract

Look-through mutagenesis (LTM) is a multidimensional mutagenesis method that simultaneously assesses and optimizes combinatorial mutations of selected amino acids. The process focuses on a precise distribution within one or more complementarity determining region (CDR) domains and explores the synergistic contribution of amino acid side-chain chemistry. LTM was applied to an anti-TNF-alpha antibody, D2E7, which is a challenging test case, because D2E7 was highly optimized (K(d) = 1 nM) by others. We selected and incorporated nine amino acids, representative of the major chemical functionalities, individually at every position in each CDR and across all six CDRs (57 aa). Synthetic oligonucleotides, each introducing one amino acid mutation throughout the six CDRs, were pooled to generate segregated libraries containing single mutations in one, two, and/or three CDRs for each V(H) and V(L) domain. Corresponding antibody libraries were displayed on the cell surface of yeast. After positive binding selection, 38 substitutions in 21 CDR positions were identified that resulted in higher affinity binding to TNF-alpha. These beneficial mutations in both V(H) and V(L) were represented in two combinatorial beneficial mutagenesis libraries and selected by FACS to produce a convergence of variants that exhibit between 500- and 870-fold higher affinities. Importantly, these enhanced affinities translate to a 15- to 30-fold improvement in in vitro TNF-alpha neutralization in an L929 bioassay. Thus, this LTM/combinatorial beneficial mutagenesis strategy generates a comprehensive energetic map of the antibody-binding site in a facile and rapid manner and should be broadly applicable to the affinity maturation of antibodies and other proteins.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15939870      PMCID: PMC1143585          DOI: 10.1073/pnas.0503543102

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  32 in total

1.  Codon usage tabulated from international DNA sequence databases: status for the year 2000.

Authors:  Y Nakamura; T Gojobori; T Ikemura
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

2.  Thermodynamic consequences of grafting enhanced affinity toward the mutated antigen onto an antibody. The case of anti-lysozyme antibody, HyHEL-10.

Authors:  Y Nishimiya; K Tsumoto; M Shiroishi; K Yutani; I Kumagai
Journal:  J Biol Chem       Date:  2000-04-28       Impact factor: 5.157

3.  Quantitative analysis of the effect of the mutation frequency on the affinity maturation of single chain Fv antibodies.

Authors:  P S Daugherty; G Chen; B L Iverson; G Georgiou
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-29       Impact factor: 11.205

Review 4.  Targeting random mutations to hotspots in antibody variable domains for affinity improvement.

Authors:  Partha S Chowdhury
Journal:  Methods Mol Biol       Date:  2002

5.  Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity.

Authors:  E T Boder; K S Midelfort; K D Wittrup
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

6.  Tech.Sight. Phage display. Affinity selection from biological libraries.

Authors:  James F Smothers; Steven Henikoff; Paul Carter
Journal:  Science       Date:  2002-10-18       Impact factor: 47.728

7.  Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen.

Authors:  Y Chen; C Wiesmann; G Fuh; B Li; H W Christinger; P McKay; A M de Vos; H B Lowman
Journal:  J Mol Biol       Date:  1999-11-05       Impact factor: 5.469

8.  Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity.

Authors:  Jennifer A Maynard; Catharina B M Maassen; Stephen H Leppla; Kathleen Brasky; Jean L Patterson; Brent L Iverson; George Georgiou
Journal:  Nat Biotechnol       Date:  2002-06       Impact factor: 54.908

9.  Complementary combining site contact residue mutations of the anti-digoxin Fab 26-10 permit high affinity wild-type binding.

Authors:  Mary K Short; Rustem A Krykbaev; Philip D Jeffrey; Michael N Margolies
Journal:  J Biol Chem       Date:  2002-02-19       Impact factor: 5.157

10.  In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin.

Authors:  Mitchell Ho; Robert J Kreitman; Masanori Onda; Ira Pastan
Journal:  J Biol Chem       Date:  2004-10-18       Impact factor: 5.157

View more
  40 in total

1.  Femtomolar Fab binding affinities to a protein target by alternative CDR residue co-optimization strategies without phage or cell surface display.

Authors:  Christian Votsmeier; Hanna Plittersdorf; Oliver Hesse; Andreas Scheidig; Michael Strerath; Uwe Gritzan; Klaus Pellengahr; Peter Scholz; Andrea Eicker; David Myszka; Wayne M Coco; Ulrich Haupts
Journal:  MAbs       Date:  2012-04-26       Impact factor: 5.857

Review 2.  Molecular engineering of antibodies for therapeutic and diagnostic purposes.

Authors:  Frédéric Ducancel; Bruno H Muller
Journal:  MAbs       Date:  2012-07-01       Impact factor: 5.857

3.  Affinity maturation of antibodies assisted by in silico modeling.

Authors:  Rodrigo Barderas; Johan Desmet; Peter Timmerman; Rob Meloen; J Ignacio Casal
Journal:  Proc Natl Acad Sci U S A       Date:  2008-06-23       Impact factor: 11.205

Review 4.  Engineering the variable region of therapeutic IgG antibodies.

Authors:  Tomoyuki Igawa; Hiroyuki Tsunoda; Taichi Kuramochi; Zenjiro Sampei; Shinya Ishii; Kunihiro Hattori
Journal:  MAbs       Date:  2011-05-01       Impact factor: 5.857

5.  Deep Sequencing-guided Design of a High Affinity Dual Specificity Antibody to Target Two Angiogenic Factors in Neovascular Age-related Macular Degeneration.

Authors:  Patrick Koenig; Chingwei V Lee; Sarah Sanowar; Ping Wu; Jeremy Stinson; Seth F Harris; Germaine Fuh
Journal:  J Biol Chem       Date:  2015-06-18       Impact factor: 5.157

Review 6.  Methods for the directed evolution of proteins.

Authors:  Michael S Packer; David R Liu
Journal:  Nat Rev Genet       Date:  2015-06-09       Impact factor: 53.242

Review 7.  Applications of Yeast Surface Display for Protein Engineering.

Authors:  Gerald M Cherf; Jennifer R Cochran
Journal:  Methods Mol Biol       Date:  2015

8.  Aglycosylated antibodies and antibody fragments produced in a scalable in vitro transcription-translation system.

Authors:  Gang Yin; Eudean D Garces; Junhao Yang; Juan Zhang; Cuong Tran; Alexander R Steiner; Christine Roos; Sunil Bajad; Susan Hudak; Kalyani Penta; James Zawada; Sonia Pollitt; Christopher J Murray
Journal:  MAbs       Date:  2012-03-01       Impact factor: 5.857

9.  Fab is the most efficient format to express functional antibodies by yeast surface display.

Authors:  Coline Sivelle; Raphaël Sierocki; Kelly Ferreira-Pinto; Stéphanie Simon; Bernard Maillere; Hervé Nozach
Journal:  MAbs       Date:  2018-05-24       Impact factor: 5.857

10.  An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10.

Authors:  Josh D Nelson; Florence M Brunel; Richard Jensen; Emma T Crooks; Rosa M F Cardoso; Meng Wang; Ann Hessell; Ian A Wilson; James M Binley; Philip E Dawson; Dennis R Burton; Michael B Zwick
Journal:  J Virol       Date:  2007-02-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.